1. Home
  2. CRSP vs GBTG Comparison

CRSP vs GBTG Comparison

Compare CRSP & GBTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • GBTG
  • Stock Information
  • Founded
  • CRSP 2013
  • GBTG 2014
  • Country
  • CRSP Switzerland
  • GBTG United States
  • Employees
  • CRSP N/A
  • GBTG N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • GBTG Computer Software: Prepackaged Software
  • Sector
  • CRSP Health Care
  • GBTG Technology
  • Exchange
  • CRSP Nasdaq
  • GBTG Nasdaq
  • Market Cap
  • CRSP 4.0B
  • GBTG 3.7B
  • IPO Year
  • CRSP 2016
  • GBTG N/A
  • Fundamental
  • Price
  • CRSP $47.25
  • GBTG $8.88
  • Analyst Decision
  • CRSP Buy
  • GBTG Strong Buy
  • Analyst Count
  • CRSP 19
  • GBTG 2
  • Target Price
  • CRSP $73.69
  • GBTG $9.75
  • AVG Volume (30 Days)
  • CRSP 1.8M
  • GBTG 827.0K
  • Earning Date
  • CRSP 11-05-2024
  • GBTG 11-05-2024
  • Dividend Yield
  • CRSP N/A
  • GBTG N/A
  • EPS Growth
  • CRSP N/A
  • GBTG N/A
  • EPS
  • CRSP N/A
  • GBTG N/A
  • Revenue
  • CRSP $202,829,000.00
  • GBTG $2,381,000,000.00
  • Revenue This Year
  • CRSP N/A
  • GBTG $7.77
  • Revenue Next Year
  • CRSP $526.27
  • GBTG $6.28
  • P/E Ratio
  • CRSP N/A
  • GBTG N/A
  • Revenue Growth
  • CRSP 19.31
  • GBTG 4.98
  • 52 Week Low
  • CRSP $43.42
  • GBTG $4.49
  • 52 Week High
  • CRSP $91.10
  • GBTG $9.04
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 44.94
  • GBTG 67.61
  • Support Level
  • CRSP $50.60
  • GBTG $8.69
  • Resistance Level
  • CRSP $59.07
  • GBTG $8.55
  • Average True Range (ATR)
  • CRSP 2.84
  • GBTG 0.34
  • MACD
  • CRSP -0.35
  • GBTG 0.11
  • Stochastic Oscillator
  • CRSP 7.48
  • GBTG 92.79

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for to treat Type 1 diabetes.

About GBTG Global Business Travel Group Inc.

Global Business Travel Group Inc operates as a business-to-business travel platform. It is engaged in providing software and services to manage travel, expenses, and meetings and events for companies of all sizes. The company is engaged in building the marketplace in B2B travel to deliver unrivaled choice, value, and experiences. It also provides business travel solutions, simplified travel management, and business consulting services. Further, The company generates revenue in two ways that involves fees and other revenues relating to processing and servicing travel transactions received from clients and travel suppliers and revenues for the provision of products and professional services not directly related to transactions received from clients, travel suppliers and Network Partners.

Share on Social Networks: